Stran je namenjena samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji.

Search

Menu

Close

PrijavaOdjava
Naša zdravilaTerapevtska področjaMedia CenterMedia CenterDogodkiGradivaVideo vsebinePovežimo sePovežimo seKontaktirajte nasMedicinske informacije družbe Pfizer

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
The broadest serotype coverage available for babies1-3Prevenar 20™ delivers the most serotype coverage in a pneumococcal conjugate vaccine (PCV), adding 7 serotypes to Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine)1-3

Prevenar 20™ and Prevenar 13® will only help protect against Streptococcus pneumoniae serotypes in their respective vaccines.1,2

There are no studies that compare the efficacy of Prevenar 20™ and PCV15.

PCV15=15-valent pneumococcal conjugate vaccine.

Prevenar 20™ includes all currently approved paediatric PCV serotypes plus 5 unique serotypes to help1-3:

  • Expand protection against additional problematic serotypes4
  • Avoid resurgence of vaccine-type pneumococcal disease due to lack of coverage13-15
Prevenar 20™ covers the most serotypes causing cases of invasive pneumococcal disease (IPD) in babies in [Country]1-3,16,17

Prevenar 20™ helps protect against 20 S. pneumoniae serotypes in the vaccine that are responsible for more disease in [Country nationality] babies than serotypes covered by any other PCV.1-3

Select a manifestation to see how expanded serotype coverage is related to pneumococcal disease case coverage.

IPD

OM

CAP

Tab Number 4

Tab Number 5

Based on data from 2018 to 2019 in children under 2 years of age in [Country], the serotypes covered by Prevenar 20™ were responsible for almost half of all invasive pneumococcal disease cases.17

This is the Second tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere u llam tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapie nte, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptati bus repudiandae obcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nesciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

This is the Third tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit. Inventore facere u llam tempore veritatis, corporis soluta animi esse dolores molestias, quisquam nam sapie nte, quo mollitia corrupti nulla! Rerum enim quis iusto.Quidem eaque odio voluptati bus repudiandae obcaecati iure dicta repellendus quod! Autem porro ducimus officiis a debitis iure unde omnis! Nesciunt odio pariatur, sequi laudantium quisquam quae dolor minus error totam.

There are no studies that compare the efficacy of Prevenar 20™ and PCV15.

The 13-serotype vaccine provides coverage for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The 15-serotype vaccine provides coverage for all serotypes covered by the 13-serotype vaccine and the additional serotypes 22F and 33F. The 20-serotype vaccine provides coverage for all serotypes covered by the 15-serotype vaccine and the additional serotypes 8, 10A, 11A, 12F, and 15B.1-3

See how each serotype covered by Prevenar 20™ is known to impact babies

Scroll left to view table
  1 3 4 5 6A 6B 7F 8 9V 10A 11A 12F 14 15B 18C 19A 19F 22F 23F 33F
Invasive pneumococcal disease5,7†
Meningitis18                
Acute otitis media19-22                
Nasopharyngeal carriage23                        
Outbreaks10,23,24                
Antibiotic resistance8,11,23-27                
Highly prevalent in [local country35]                                      

†Includes meningitis, bacteraemia, and pneumonia.28

Prevenar 20™ is built on a foundation of Prevenar‡ vaccine efficacy and effectiveness1,2,29Proven efficacy against IPD and otitis media (OM) in clinical trials for Prevenar® (Pneumococcal 7-valent Conjugate Vaccine)2,29,30

Select a manifestation to review Prevenar® (PCV7) clinical trial efficacy results.

IPD

OM

Tab Number 3

IPD

OM

Prevenar® (PCV7) study in IPD2,29

Randomised, controlled trial conducted in the United States of 30,258 babies receiving Prevenar® (PCV7) or a control vaccine at 2, 4, 6, and 12 to 15 months of age, followed from October 1995 to April 1999.

Prevenar® (PCV7) OM study design30

Double-blind vaccine efficacy trial conducted in Finland in which 1662 babies were equally randomised to receive either Prevenar® (PCV7) or a control vaccine, Recombivax HB (Hepatitis B Vaccine [Recombinant]), at approximately 2, 4, 6, and 12 to 14 months of age.

§OM efficacy data are only available for S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.30CI=confidence interval; PCV7=7-valent pneumococcal conjugate vaccine.Recombivax HB is a registered trademark of Merck & Co., Inc.

Prevenar 20™ and Prevenar 13® were licenced based on immunogenicity endpoints.
Prevenar 13® efficacy was inferred by showing noninferiority to Prevenar® (PCV7).
Prevenar 20™ efficacy was inferred by showing noninferiority to Prevenar 13®.1,2,29

Prevenar 20™ is the next generation of Prevenar,‡ providing a new level of paediatric protection against IPD.1
Example TextPrevenar includes Prevenar® (PCV7) and Prevenar 13®. In [Country], Prevenar® (PCV7) was available from 2001 to 2010, and Prevenar 13® has been available since 2010.2,31,3520+ years of demonstrated effectiveness in IPD prevention in young children with Prevenar‡ vaccines2Prevenar‡ vaccines have demonstrated effectiveness at helping to protect against vaccine-type IPD in young children for nearly 2 decades in [Country].16,32

Since the introduction of Prevenar® (PCV7) in 2006 and Prevenar 13® in 2010, the serotype coverage provided by these vaccines has reduced vaccine-type IPD in children under 2 years of age by about 87%.16,32Incidence of IPD16,32

GNRCS surveillance data in children <2 years old in [Country]II

Higher-valent PCVs are needed to address rising burden of non-vaccine type IPD in babies.32

Nearly 300 million babies have been vaccinated with Prevenar‡ vaccines globally.33
Example TextPrevenar includes Prevenar® and Prevenar 13®. In [Country], Prevenar® (PCV7) was available from 2001 to 2010, and Prevenar 13® has been available since 2010.2,31,35The GNRCS has been collecting IPD isolates from children in Germany since 1997, serotyped using the Neufeld Quellung reaction.16In Germany, Prevenar® (PCV7) was available in 2001 and recommended by STIKO for children with an increased risk for pneumococcal disease only. Universal vaccination of all children <2 years of age was recommended in 2006. In 2009, Prevenar® (PCV7) was replaced by the higher-valent vaccine Prevenar 13®.32GNRCS=German National Reference Center for Streptococci; STIKO=Standing Committee on Vaccination.

References:

Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Senders S, Klein NP, Lamberth E, et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States. Pediatr Infect Dis J. 2021;40(10):944-951.Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113.Hausdorff WP, Hanage WP. Interim results of an ecological experiment—conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358-374.Moore MR, Link-Gelles R, Schaffner W, et al. Impact of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301-309.Metcalf BJ, Gertz RE Jr, Gladstone RA, et al; Active Bacterial Core surveillance team. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;22(1):60.e9-60.e29.Schillberg E, Isaac M, Deng X, et al. Outbreak of invasive Streptococcus pneumoniae serotype 12F among a marginalized inner-city population in Winnipeg, Canada, 2009-2011. Clin Infect Dis. 2014;59(5):651-657.Zivich PN, Grabenstein JD, Becker-Dreps SI, Weber DJ. Streptococcus pneumoniae outbreaks and implications for transmission and control: a systematic review. Pneumonia (Nathan). 2018;10:11.Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119-1125.Mendes RE, Hollingsworth RC, Costello A, et al. Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. Antimicrob Agents Chemother. 2015;59(9):5595-5601.Desmet S, Verhaegen J, Van Ranst M, Peetermans W, Lagrou K. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018;18(8):830-831.Wouters I, Van Heirstraeten L, Desmet S, et al. Nasopharyngeal S. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. Vaccine. 2018;36(1):15-22.Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066-1073.van der Linden M, Itzek A, Perniciaro S, Imöhl M. Invasive pneumococcal disease among children in Germany, ten years after PCV13 introduction. Poster presented online at: The European Society for Paediatric Infectious Diseases 2020 Virtual Meeting; October 28, 2020.van der Linden M, Perniciaro S, Imöhl M. Invasive pneumococcal disease among children in Germany, ten years after PCV13 introduction. Abstract P0325 presented online at: The European Society for Paediatric Infectious Diseases 2020 Virtual Meeting; October 28, 2020.Garcia Quesada M, Yang Y, Bennett JC, et al; the PSERENADE Team. Serotype distribution of remaining pneumococcal meningitis in the mature PCV10/13 period: findings from the PSERENADE Project. Microorganisms. 2021;9(4):738.Hausdorff WP, Yothers G, Dagan R, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J. 2002;21(11):1008-1016.Kaur R, Fuji N, Pichichero ME. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019. Eur J Clin Microbiol Infect Dis. 2022;41(1):37-44.Morales M, Ludwig G, Ercibengoa M, et al. Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain. PLoS One. 2018;13(12):e0209048.Levy C, Varon E, Ouldali N, et al. Bacterial causes of otitis media with spontaneous perforation of the tympanic membrane in the era of 13 valent pneumococcal conjugate vaccine. PLoS One. 2019;14(2):e0211712.Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5(2):83-93.Pitts SI, Apostolou A, DasGupta S, et al. Serotype 10A in case patients with invasive pneumococcal disease: a pilot study of PCR-based serotyping in New Jersey. Public Health Rep. 2015;130(1):54-59.Park DC, Kim SH, Yong D, et al. Serotype distribution and antimicrobial resistance of invasive and noninvasive Streptococcus pneumoniae isolates in Korea between 2014 and 2016. Ann Lab Med. 2019;39(6):537-544.Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis. 2013;19(7):1074-1083.Kawaguchiya M, Urushibara N, Aung MS, Shinagawa M, Takahashi S, Kobayashi N. Serotype distribution, antimicrobial resistance and prevalence of pilus islets in pneumococci following the use of conjugate vaccines. J Med Microbiol. 2017;66(5):643-650.Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25(3):409-419.Black S, Shinefield H. Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur J Pediatr. 2002;161(suppl 2):S127-S131.Eskola J, Kilpi T, Palmu A, et al; Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344(6):403-409.Prevenar® (Pneumococcal 7-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2011.van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257.Chapman R, Sutton K, Dillon-Murphy D, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis. Vaccine. 2020;38(45):7138-7145.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.Local approval dates.About Robust immune response with Prevenar 20™ after [__] doses1 Review trial results Loading [Local body] recommends   Prevenar 20™ for routine infant vaccination34 Learn more Loading
PP-PNR-GLB-0425 March 2024
PfizerPro računPfizerPro račun

Za dostop do dodatnih gradiv, vsebin in prejemanje sporočil o zdravilih in cepivih družbe Pfizer

VpisRegistracijaRačunOdjava

To spletno mesto je namenjeno samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji. Če se uvrščate med širšo javnost in bi želeli dostopati do informacij o določenem zdravilu, se, prosimo, obrnite na vašega zdravnika ali farmacevta.

 

To spletno stran vam ponuja Pfizer, podružnica Ljubljana.

 

Avtorske pravice 2022 Pfizer, podružnica Ljubljana. Vse pravice pridržane.


Davčna številka: SI 17966086

PP-UNP-SVN-0142, datum priprave: september 2023
Zapuščate PfizerPro
​
Zapuščate spletno mesto, ki ga upravlja Pfizer. Povezave do vseh zunanjih spletnih mest so na voljo kot vir za naše obiskovalce. Pfizer ne prevzema odgovornosti za vsebino spletnih mest, ki niso v lasti in upravljanju družbe Pfizer.
 
PP-UNP-SVN-0142
datum priprave: september 2023
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​